

Kyowa Hakko Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary Fiscal 2014 First Quarter

(January 1, 2014 - March 31, 2014)

- This document was made as a supplement to the Kessan Tanshin (financial report), disclosed at the Tokyo Stock Exchange on April 24, for the first quarter of Fiscal 2014, the three-month period from January 1, 2014 to March 31, 2014.
- This document contains forward-looking statements based on a member of assumptions and beliefs held by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.
- Figures presented in this document have been rounded down to the nearest whole number.

Index	Page
I. Consolidated Financial Results	
1. Trends in consolidated income	1
2. Trends in results by segment	2
3. Other trends	3
II. Consolidated Balance Sheets	4
III. Consolidated Subsidiaries and Affiliates	5
IV. Kyowa Hakko Kirin Sales of Main Products	6
V. Segment Information and Main Subsidiaries Operating Profit or Loss	
1. Pharmaceuticals segment	8
2. Bio-Chemicals segment	9
VI. R&D Pipeline	10

The average exchange rate for each period was as follows

Unit: yen

	2013 results				2014 results				2014 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
US \$	89	94	95	96	103				100	100
EURO	118	123	125	127	141				130	130
GBP	141	145	147	150	171				155	155

Contact
 Kyowa Hakko Kirin Co., Ltd.
 Corporate Communications Department
 Tel 81 3 3282 0009

I. Consolidated Financial Results

1. Trends in consolidated income

Accumulative

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY2014 Forecast				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	86.6	169.7	252.1	340.6	86.0	(0.5)	99%	-	-	-	-	-	-	163.0	96%	337.0	99%
Gross Profit	52.3	105.1	157.2	212.7	51.2	(1.0)	98%	-	-	-	-	-	-	-	-	-	-
Selling, general and administrative expenses	37.8	77.9	115.8	160.9	38.8	0.9	103%	-	-	-	-	-	-	-	-	-	-
Operating income (prior to amortization of goodwill)	16.7	31.8	48.3	61.0	14.7	(2.0)	88%	-	-	-	-	-	-	20.6	65%	50.2	82%
Operating income	14.4	27.1	41.4	51.7	12.4	(2.0)	86%	-	-	-	-	-	-	16.0	59%	41.0	79%
Non-operating income	1.0	2.4	2.9	4.4	1.0	(0.0)	96%	-	-	-	-	-	-	-	-	-	-
Non-operating expenses	0.6	3.0	5.1	6.7	1.3	0.7	207%	-	-	-	-	-	-	-	-	-	-
Ordinary income	14.8	26.5	39.2	49.5	12.0	(2.7)	81%	-	-	-	-	-	-	-	-	35.0	71%
Extraordinary income	3.8	4.4	4.9	4.9	0.3	(3.5)	8%	-	-	-	-	-	-	-	-	-	-
Extraordinary loss	-	0.1	3.6	4.7	-	-	-	-	-	-	-	-	-	-	-	-	-
Income before income taxes and minority interests	18.6	30.8	40.4	49.7	12.3	(6.2)	66%	-	-	-	-	-	-	-	-	34.5	69%
Income taxes	8.1	13.1	17.1	19.6	6.0	(2.1)	74%	-	-	-	-	-	-	-	-	-	-
Minority interests in income	0.0	0.0	0.0	0.0	-	(0.0)	-	-	-	-	-	-	-	-	-	-	-
Net income	10.4	17.6	23.3	30.0	6.3	(4.1)	60%	-	-	-	-	-	-	-	-	20.0	66%
Comprehensive income	16.8	28.9	36.7	51.8	3.8	(12.9)	23%	-	-	-	-	-	-	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	23.39	40.75	55.29	71.85	15.80	(7.59)	68%	-	-	-	-	-	-	-	-	53.45	74%

* "Prior to amortization of goodwill" refers to profits prior to the deduction of amortization of the goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).
(Note: This adjustment does not include goodwill amortization in respect of the acquisition of ProStrakan.)

* There are no changes to the forecasts for the fiscal year ending December 31, 2014 announced on January 31, 2014.

Quarterly

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change Amount	%	Apr - Jun	%	Jul - Sep	%	Oct - Dec	%
Net sales	86.6	83.0	82.3	88.5	86.0	(0.5)	99%	-	-	-	-	-	-
Gross Profit	52.3	52.7	52.1	55.4	51.2	(1.0)	98%	-	-	-	-	-	-
Selling, general and administrative expenses	37.8	40.0	37.8	45.1	38.8	0.9	103%	-	-	-	-	-	-
Operating income (Prior to amortization of goodwill)	16.7	15.0	16.5	12.6	14.7	(2.0)	88%	-	-	-	-	-	-
Operating income	14.4	12.7	14.2	10.3	12.4	(2.0)	86%	-	-	-	-	-	-
Non-operating income	1.0	1.3	0.5	1.4	1.0	(0.0)	96%	-	-	-	-	-	-
Non-operating expenses	0.6	2.3	2.1	1.5	1.3	0.7	207%	-	-	-	-	-	-
Ordinary income	14.8	11.6	12.6	10.2	12.0	(2.7)	81%	-	-	-	-	-	-
Extraordinary income	3.8	0.6	0.5	0.0	0.3	(3.5)	8%	-	-	-	-	-	-
Extraordinary loss	-	0.1	3.5	1.0	-	-	-	-	-	-	-	-	-
Income before income taxes and minority interestses	18.6	12.2	9.6	9.2	12.3	(6.2)	66%	-	-	-	-	-	-
Income taxes	8.1	4.9	3.9	2.4	6.0	(2.1)	74%	-	-	-	-	-	-
Minority interests in income	0.0	0.0	0.0	0.0	-	(0.0)	-	-	-	-	-	-	-
Net income	10.4	7.1	5.6	6.7	6.3	(4.1)	60%	-	-	-	-	-	-
EPS prior to amortization of goodwill (¥/share)	23.39	17.36	14.54	16.57	15.80	(7.59)	68%	-	-	-	-	-	-

I. Consolidated Financial Results

2. Trends in results by segment

(1) Reported segment

Accumulative

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY2014 Forecast				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	86.6	169.7	252.1	340.6	86.0	(0.5)	99%	-	-	-	-	-	-	163.0	96%	337.0	99%
Pharmaceuticals	67.4	129.9	192.7	261.0	63.1	(4.2)	94%	-	-	-	-	-	-	119.0	92%	250.0	96%
Bio-Chemicals	19.9	41.2	61.5	82.9	23.5	3.5	118%	-	-	-	-	-	-	45.5	110%	90.0	109%
Total	87.4	171.1	254.3	343.9	86.7	(0.6)	99%	-	-	-	-	-	-	164.5	96%	340.0	99%
Eliminations	(0.7)	(1.4)	(2.2)	(3.3)	(0.6)	0.0	-	-	-	-	-	-	-	(1.5)	-	(3.0)	-
Operating income	14.4	27.1	41.4	51.7	12.4	(2.0)	86%	-	-	-	-	-	-	16.0	59%	41.0	79%
Before goodwill amortization	16.7	31.8	48.3	61.0	14.7	(2.0)	88%	-	-	-	-	-	-	20.6	65%	50.2	82%
Pharmaceuticals	13.0	24.1	36.9	46.1	9.4	(3.6)	72%	-	-	-	-	-	-	12.0	50%	33.0	72%
	15.2	28.4	43.4	54.7	11.5	(3.6)	76%	-	-	-	-	-	-	16.3	57%	41.6	76%
Bio-Chemicals	1.4	3.1	4.5	5.6	3.0	1.5	206%	-	-	-	-	-	-	4.0	129%	8.0	141%
	1.6	3.4	4.9	6.2	3.2	1.5	196%	-	-	-	-	-	-	4.3	126%	8.6	137%
Total	14.5	27.2	41.4	51.8	12.4	(2.0)	86%	-	-	-	-	-	-	16.0	59%	41.0	79%
	16.8	31.8	48.4	61.0	14.8	(2.0)	88%	-	-	-	-	-	-	20.6	65%	50.2	82%
Eliminations	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	-	-	-	-	-	-	-	-	-	-	-

Quarterly

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change Amount	%	Apr - Jun	%	Jul - Sep	%	Oct - Dec	%
Net sales	86.6	83.0	82.3	88.5	86.0	(0.5)	99%	-	-	-	-	-	-
Pharmaceuticals	67.4	62.5	62.8	68.2	63.1	(4.2)	94%	-	-	-	-	-	-
Bio-Chemicals	19.9	21.2	20.3	21.3	23.5	3.5	118%	-	-	-	-	-	-
Total	87.4	83.7	83.2	89.5	86.7	(0.6)	99%	-	-	-	-	-	-
Eliminations	(0.7)	(0.6)	(0.8)	(1.0)	(0.6)	0.0	-	-	-	-	-	-	-
Operating income	14.4	12.7	14.2	10.3	12.4	(2.0)	86%	-	-	-	-	-	-
Before goodwill amortization	16.7	15.0	16.5	12.6	14.7	(2.0)	88%	-	-	-	-	-	-
Pharmaceuticals	13.0	11.0	12.8	9.1	9.4	(3.6)	72%	-	-	-	-	-	-
	15.2	13.2	14.9	11.3	11.5	(3.6)	76%	-	-	-	-	-	-
Bio-Chemicals	1.4	1.6	1.4	1.1	3.0	1.5	206%	-	-	-	-	-	-
	1.6	1.7	1.5	1.3	3.2	1.5	196%	-	-	-	-	-	-
Total	14.5	12.6	14.2	10.3	12.4	(2.0)	86%	-	-	-	-	-	-
	16.8	15.0	16.5	12.6	14.8	(2.0)	88%	-	-	-	-	-	-
Eliminations	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	-	-	-	-	-	-	-

(2) Regional sales

Billions of yen, rounded down

	FY 2013 results								FY 2014 results							
	Jan - Mar	% of consolidated sales	Jan - Jun	% of consolidated sales	Jan - Sep	% of consolidated sales	Jan - Dec	% of consolidated sales	Jan - Mar	% of consolidated sales	Jan - Jun	% of consolidated sales	Jan - Sep	% of consolidated sales	Jan - Dec	% of consolidated sales
Japan sales	66.1	76.3%	127.7	75.3%	188.9	75.0%	254.0	74.6%	61.8	71.9%	-	-	-	-	-	-
Overseas sales	20.5	23.7%	41.9	24.7%	63.1	25.0%	86.5	25.4%	24.2	28.1%	-	-	-	-	-	-
America	5.2	6.0%	11.1	6.6%	16.3	6.5%	23.9	7.0%	5.5	6.4%	-	-	-	-	-	-
Europe	9.4	10.9%	18.5	10.9%	28.1	11.1%	37.2	10.9%	11.0	12.8%	-	-	-	-	-	-
Asia	5.7	6.6%	11.8	7.0%	18.0	7.1%	24.4	7.2%	7.3	8.5%	-	-	-	-	-	-
Other regions	0.1	0.2%	0.3	0.2%	0.6	0.3%	0.9	0.3%	0.2	0.3%	-	-	-	-	-	-
Total consolidated net sales	86.6	100%	169.7	100%	252.1	100%	340.6	100.0%	86.0	100%	-	-	-	-	-	-

* Sales classified by region or country based on location of customer.

I. Consolidated Financial Results

3. Other trends

(1) R&D Expenses

Billions of yen, rounded down

	FY 2013 results				FY 2014 results				FY 2014 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
R&D expenses	10.6	21.0	30.7	43.6	10.3	-	-	-	24.0	47.0
<i>R&D to net sales ratio</i>	12.3%	12.4%	12.2%	12.8%	12.0%	-	-	-	14.7%	13.9%
Pharmaceuticals	9.8	19.3	28.3	40.4	9.5	-	-	-	22.2	43.5
<i>R&D to net sales ratio</i>	14.7%	14.9%	14.7%	15.5%	15.2%	-	-	-	18.7%	17.4%
Bio-Chemicals	0.7	1.6	2.4	3.2	0.7	-	-	-	1.8	3.5

(2) Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2013 results				FY 2014 results				FY 2014 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Capital expenditure	5.3	9.6	16.6	24.8	5.3	-	-	-	15.2	30.0
Pharmaceuticals	1.8	4.4	7.4	12.6	2.8	-	-	-	10.2	18.4
Bio-Chemicals	3.5	5.1	9.2	12.2	2.4	-	-	-	5.0	11.6

(3) Depreciation and Amortization Expenses (Tangible and intangible fixed assets)

Billions of yen, rounded down

	FY 2013 results				FY 2014 results				FY 2014 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Depreciation and amortization expenses	4.8	9.9	15.5	21.5	5.2	-	-	-	10.8	22.7
<i>Amortization of intangible fixed assets</i>	1.5	3.1	4.9	6.9	1.9	-	-	-	3.7	7.5
Pharmaceuticals	3.3	6.8	10.7	14.9	3.6	-	-	-	7.6	16.1
<i>Amortization of intangible fixed assets</i>	1.5	3.1	4.9	6.9	1.9	-	-	-	3.7	7.5
Bio-Chemicals	1.5	3.0	4.7	6.6	1.5	-	-	-	3.2	6.6

*Depreciation expenses for intangible fixed assets do not include goodwill amortization expenses

(4) Goodwill Amortization Expenses

Billions of yen, rounded down

	FY 2013 results				FY 2014 results				FY 2014 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Amortization expenses	2.8	5.7	8.6	11.5	3.0	-	-	-	5.9	11.9
<i>Reverse acquisition goodwill amortization expenses</i>	2.3	4.6	6.9	9.2	2.3	-	-	-	4.6	9.2
Pharmaceuticals	2.7	5.4	8.1	10.9	2.8	-	-	-	5.5	11.0
<i>Reverse acquisition goodwill amortization expenses</i>	2.1	4.3	6.4	8.6	2.1	-	-	-	4.3	8.6
Bio-Chemicals	0.1	0.3	0.4	0.6	0.2	-	-	-	0.4	0.9
<i>Reverse acquisition goodwill amortization expenses</i>	0.1	0.3	0.4	0.6	0.1	-	-	-	0.3	0.6

*Reverse acquisition goodwill amortization expenses" refers to amortization of goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).

II. Consolidated Balance Sheets

Billions of yen, rounded down

	2012	2013				2014				
	Dec 31	Mar 31	June 30	Sep 30	Dec 31	Mar 31	Change previous year end	June 30	Sep 30	Dec 31
Assets	679.3	694.1	691.4	691.2	719.2	689.9	(29.2)	-	-	-
Current assets	303.9	310.0	306.5	305.5	329.3	300.8	(28.4)	-	-	-
Cash and deposits	21.5	23.2	24.8	21.4	20.1	17.2	(2.9)	-	-	-
Notes and accounts receivable-trade	101.5	103.5	98.5	92.0	98.6	102.9	4.3	-	-	-
Inventories	63.4	68.7	70.9	72.8	75.7	78.9	3.2	-	-	-
Deferred tax assets	10.3	10.6	10.6	10.7	10.4	10.2	(0.2)	-	-	-
Short-term loans receivable	98.1	97.3	94.1	101.1	113.1	85.1	(27.9)	-	-	-
Other	8.8	6.5	7.3	7.4	11.2	6.3	(4.9)	-	-	-
Noncurrent assets	375.3	384.0	384.8	385.7	389.9	389.0	(0.8)	-	-	-
Property, plant and equipment	126.8	129.6	130.2	133.4	137.9	139.4	1.5	-	-	-
Buildings and structures	40.7	40.5	40.4	40.4	42.2	41.3	(0.8)	-	-	-
Machinery, equipment and vehicles	19.3	19.0	19.8	19.5	21.0	21.5	0.4	-	-	-
Land	53.3	55.2	54.8	54.6	54.6	54.5	(0.0)	-	-	-
Other	13.3	14.7	15.1	18.7	20.0	21.9	1.9	-	-	-
Intangible assets	207.5	214.5	212.9	210.9	212.0	207.6	(4.4)	-	-	-
Goodwill	168.8	166.7	165.2	163.7	163.7	161.6	(2.0)	-	-	-
Marketing rights	36.2	45.5	45.5	45.2	46.5	44.3	(2.1)	-	-	-
Other	2.4	2.2	2.1	1.9	1.8	1.6	(0.2)	-	-	-
Investments and other assets	40.9	39.9	41.7	41.3	39.9	41.9	2.0	-	-	-
Investment securities	23.6	22.9	24.7	24.0	24.6	23.4	(1.1)	-	-	-
Deferred tax assets	7.7	6.7	6.3	6.4	3.8	3.9	0.0	-	-	-
Other	9.5	10.2	10.6	10.9	11.4	14.5	3.1	-	-	-
Liabilities	123.4	126.9	112.0	110.9	123.8	98.4	(25.3)	-	-	-
Current liabilities	85.7	89.9	77.3	73.1	85.0	76.7	(8.3)	-	-	-
Notes and accounts payable-trade	26.3	30.5	23.4	17.9	22.5	26.0	3.4	-	-	-
Short-term loans payable	5.6	5.7	5.8	5.5	6.2	4.8	(1.3)	-	-	-
Accounts payable-other	29.0	32.5	26.5	26.4	36.5	27.3	(9.1)	-	-	-
Income taxes payable	15.7	8.0	12.8	11.2	10.4	5.4	(5.0)	-	-	-
Provision	1.2	5.1	1.2	5.2	1.8	5.5	3.7	-	-	-
Other	7.7	7.8	7.4	6.7	7.4	7.5	0.0	-	-	-
Noncurrent liabilities	37.6	36.9	34.6	37.7	38.7	21.7	(17.0)	-	-	-
Deferred tax liabilities	11.2	11.3	11.5	11.4	11.8	11.3	(0.4)	-	-	-
Provision	19.9	19.5	19.6	22.9	22.9	6.4	(16.5)	-	-	-
Other	6.4	6.0	3.4	3.4	3.9	3.9	(0.0)	-	-	-
Net assets	555.8	567.2	579.3	580.3	595.4	591.4	(3.9)	-	-	-
Shareholders' equity	560.6	565.6	572.8	571.6	578.3	577.8	(0.4)	-	-	-
Capital stock	26.7	26.7	26.7	26.7	26.7	26.7	-	-	-	-
Capital surplus	512.3	512.3	512.3	512.3	512.3	512.3	(0.0)	-	-	-
Retained earnings	48.1	53.1	60.3	59.1	65.8	65.3	(0.5)	-	-	-
Treasury stock	(26.5)	(26.5)	(26.5)	(26.5)	(26.6)	(26.5)	0.0	-	-	-
Accumulated other comprehensive income	(5.7)	0.4	5.2	7.4	15.6	13.3	(2.2)	-	-	-
Valuation difference on available-for-sale securities	(2.2)	(0.0)	0.9	1.0	1.4	1.2	(0.2)	-	-	-
Foreign currency translation adjustment	(3.5)	0.4	4.2	6.3	14.2	12.1	(2.0)	-	-	-
Subscription rights to shares	0.2	0.2	0.2	0.2	0.3	0.2	(0.0)	-	-	-
Minority interests	0.8	0.9	1.0	1.0	1.1	-	(1.1)	-	-	-
Total liabilities and net assets	679.3	694.1	691.4	691.2	719.2	689.9	(29.2)	-	-	-

III. Consolidated Subsidiaries and Affiliates

(As of March 31, 2014)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sales of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
			Chiyoda Kaihatsu Co., Ltd.	100.0%	Contracting, wholesale and retail and insurance agency business
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Supervision and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of antibody technology and accelerating research collaborations (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of new candidate substances under contract (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generation of new candidate substances under contract (US)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
			ProStrakan Group plc	100.0%	Supervision and management of subsidiaries (UK)
			Strakan International S.a r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
		Europe	Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
			ProStrakan AB	100.0%	Sales of pharmaceuticals (Sweden)
	Asia	Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)	
Kyowa Hakko Kirin Korea Co., Ltd.		100.0%	Sales of pharmaceuticals (Korea)		
Kyowa Hakko Kirin (Taiwan) Co., Ltd.		100.0%	Sales of pharmaceuticals (Taiwan)		
Kyowa Hakko Kirin (Hong Kong) Co., Ltd.		100.0%	Sales of pharmaceuticals (Hong Kong)		
Kyowa Hakko Kirin (Singapore) Pte. Ltd.		100.0%	Research and sale of pharmaceuticals (Singapore)		
Affiliate accounted for by the equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar pharmaceuticals	
		Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial alcohol	
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and healthcare products
			DAIICHI FINE CHEMICAL CO., LTD.	100.0%	Manufacture and sales of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
		The Americas	BIOKYOWA INC.	100.0%	Manufacture and sales of amino acids (US)
			KYOWA HAKKO U.S.A., INC.	100.0%	Sales of fine chemicals including amino acids (US)
			Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Supervision and management of subsidiaries (US)
		Europe	KYOWA HAKKO Europe GmbH	100.0%	Sales of fine chemicals including amino acids (Germany)
			Kyowa Hakko Bio Italia S.r.l.	100.0%	Sales of fine chemicals including amino acids (Italy)
		Asia	SHANGHAI KYOWA AMINO ACID CO., LTD.	100.0%	Manufacture and sales of amino acids (China)
			THAI KYOWA BIOTECHNOLOGIES CO., LTD.	100.0%	Manufacture and sales of amino acids (Thailand)
			KYOWA HAKKO (H.K.) CO., LTD.	100.0%	Sales of fine chemicals including amino acids (Hong Kong)
			KYOWA HAKKO BIO SINGAPORE PTE. LTD.	100.0%	Sales of fine chemicals including amino acids (Singapore)

Changes in scope of consolidation resulting in changes in subsidiaries (January 1, 2014 - March 31, 2014)

New: None

Exclusions: None

IV. Kyowa Hakko Kirin Sales of main products

Accumulative

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Kyowa Hakko Kirin total	56.4	106.4	157.0	210.9	52.1	(4.3)	92%	-	-	-	-	-	-	97.1	91%	203.1	96%
Indication / Product name																	
<i>ESA formulation</i> Nesp	10.6	25.0	39.7	56.0	12.1	1.5	114%	-	-	-	-	-	-	26.0	104%	54.1	97%
<i>ESA formulation</i> Espo	0.7	1.5	2.3	3.2	0.6	(0.0)	86%	-	-	-	-	-	-	1.2	82%	2.5	79%
Nesp/Espo	11.3	26.5	42.1	59.2	12.8	1.4	112%	-	-	-	-	-	-	27.3	103%	56.7	96%
<i>Secondary hyperparathyroidism</i> Regpara	3.0	6.9	10.6	15.1	4.5	1.4	148%	-	-	-	-	-	-	7.6	111%	16.0	105%
<i>Secondary hyperparathyroidism</i> Rocaltrol	0.7	1.8	2.8	4.1	1.1	0.3	143%	-	-	-	-	-	-	1.9	110%	4.2	104%
<i>Type-2 diabetes</i> Onglyza	-	-	1.1	1.1	0.0	0.0	-	-	-	-	-	-	-	0.7	-	2.5	219%
<i>Cardiovascular</i> Coniel	3.5	7.6	11.3	15.5	3.2	(0.3)	91%	-	-	-	-	-	-	6.4	84%	12.4	80%
<i>Cardiovascular (Hypertension)</i> Coversyl	0.7	1.6	2.5	3.4	0.7	(0.0)	95%	-	-	-	-	-	-	1.5	93%	3.0	88%
G-CSF Gran	2.5	5.8	9.0	12.4	2.0	(0.4)	81%	-	-	-	-	-	-	4.5	78%	8.5	69%
<i>Transdermal persistent cancer pain</i> Fentos	1.0	2.3	3.7	5.3	1.1	0.1	114%	-	-	-	-	-	-	2.7	118%	6.4	119%
<i>Anticancer</i> Poteligeo	0.2	0.5	0.8	1.1	0.2	(0.0)	97%	-	-	-	-	-	-	0.9	171%	2.0	175%
<i>Anticancer</i> 5-FU	0.6	1.3	2.0	2.7	0.5	(0.0)	93%	-	-	-	-	-	-	1.2	93%	2.4	91%
<i>Anticancer</i> Navelbine	0.2	0.5	0.8	1.1	0.2	(0.0)	83%	-	-	-	-	-	-	0.4	82%	0.8	78%
<i>Chronic idiopathic thrombocytopenic purpura</i> Romiplate	0.4	1.1	1.7	2.5	0.5	0.1	122%	-	-	-	-	-	-	1.2	117%	2.6	104%
<i>Antiallergenic</i> Allelock	10.7	15.9	20.9	27.6	8.4	(2.3)	78%	-	-	-	-	-	-	13.9	87%	23.7	86%
<i>Antiallergic eyedrops</i> Patanol	9.4	10.1	11.4	13.4	7.1	(2.3)	75%	-	-	-	-	-	-	8.5	85%	12.0	90%
<i>Inflammatory bowel disease</i> Asacol	1.0	2.4	3.8	5.4	1.5	0.4	140%	-	-	-	-	-	-	2.8	117%	6.0	111%
<i>Parkinson's disease</i> Nourias	-	0.0	0.2	0.5	0.2	0.2	-	-	-	-	-	-	-	1.0	-	3.8	735%
<i>Antiepileptic</i> Depakene	2.3	5.0	7.7	10.5	2.3	(0.0)	100%	-	-	-	-	-	-	4.9	97%	9.8	93%
<i>Gastrointestinal</i> Nauzelin	1.0	2.1	3.1	4.5	1.0	(0.0)	99%	-	-	-	-	-	-	2.1	101%	4.4	98%
Exports and Technology Out-Licensing																	
Exports	3.2	5.4	8.1	10.4	3.4	0.2	107%	-	-	-	-	-	-	6.0	111%	10.5	101%
Technology Out-Licensing	4.8	9.7	13.8	15.3	2.0	(2.8)	42%	-	-	-	-	-	-	4.7	49%	14.3	94%

IV. Kyowa Hakko Kirin Sales of main products

Quarterly

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change amount	%	Apr - Jun	%	Jul - Sep	%	Oct - Dec	%
Kyowa Hakko Kirin total	56.4	50.0	50.5	53.8	52.1	(4.3)	92%	-	-	-	-	-	-
Indication / Product name													
ESA formulation Nesp	10.6	14.3	14.7	16.3	12.1	1.5	114%	-	-	-	-	-	-
ESA formulation Espo	0.7	0.8	0.8	0.8	0.6	(0.0)	86%	-	-	-	-	-	-
Nesp/Espo	11.3	15.2	15.5	17.1	12.8	1.4	112%	-	-	-	-	-	-
Secondary hyperparathyroidism Regpara	3.0	3.8	3.7	4.4	4.5	1.4	148%	-	-	-	-	-	-
Secondary hyperparathyroidism Rocaltrol	0.7	1.0	1.0	1.2	1.1	0.3	143%	-	-	-	-	-	-
Type-2 diabetes Onglyza	-	-	1.1	0.0	0.0	0.0	-	-	-	-	-	-	-
Cardiovascular Coniel	3.5	4.0	3.7	4.1	3.2	(0.3)	91%	-	-	-	-	-	-
Cardiovascular (Hypertension) Coversyl	0.7	0.9	0.8	0.9	0.7	(0.0)	95%	-	-	-	-	-	-
G-CSF Gran	2.5	3.2	3.1	3.4	2.0	(0.4)	81%	-	-	-	-	-	-
Transdermal persistent cancer pain Fentos	1.0	1.3	1.3	1.6	1.1	0.1	114%	-	-	-	-	-	-
Anticancer Poteligeo	0.2	0.2	0.3	0.3	0.2	(0.0)	97%	-	-	-	-	-	-
Anticancer 5-FU	0.6	0.7	0.6	0.7	0.5	(0.0)	93%	-	-	-	-	-	-
Anticancer Navelbine	0.2	0.2	0.2	0.2	0.2	(0.0)	83%	-	-	-	-	-	-
Chronic idiopathic thrombocytopenic purpura Romiplate	0.4	0.6	0.6	0.7	0.5	0.1	122%	-	-	-	-	-	-
Antiallergenic Allelock	10.7	5.2	4.9	6.7	8.4	(2.3)	78%	-	-	-	-	-	-
Antiallergic eyedrops Patanol	9.4	0.6	1.3	1.9	7.1	(2.3)	75%	-	-	-	-	-	-
Inflammatory bowel disease Asacol	1.0	1.3	1.4	1.6	1.5	0.4	140%	-	-	-	-	-	-
Parkinson's disease Nouria	-	0.0	0.1	0.2	0.2	0.2	-	-	-	-	-	-	-
Antiepileptic Depakene	2.3	2.7	2.6	2.8	2.3	(0.0)	100%	-	-	-	-	-	-
Gastrointestinal Nauzelin	1.0	1.1	0.9	1.4	1.0	(0.0)	99%	-	-	-	-	-	-
Exports and Technology Out-Licensing													
Exports	3.2	2.2	2.6	2.3	3.4	0.2	107%	-	-	-	-	-	-
Technology Out-Licensing	4.8	4.8	4.0	1.5	2.0	(2.8)	42%	-	-	-	-	-	-

V. Segment information and main subsidiaries operating profit or loss

1. Pharmaceuticals segment

(1) Pharmaceuticals segment consolidated total

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	67.4	129.9	192.7	261.0	63.1	(4.2)	94%	-	-	-	-	-	-	119.0	92%	250.0	96%
Japan sales	55.2	105.7	155.8	209.3	49.6	(5.6)	90%	-	-	-	-	-	-	92.4	87%	199.1	95%
Overseas sales	12.1	24.2	36.9	51.6	13.5	1.4	112%	-	-	-	-	-	-	26.5	110%	50.8	98%
America	3.3	7.0	10.3	15.8	3.4	0.1	103%	-	-	-	-	-	-	6.8	98%	12.8	81%
Europe	5.8	10.9	17.1	23.0	6.8	1.0	118%	-	-	-	-	-	-	13.2	121%	24.8	108%
Asia and others	2.9	6.2	9.4	12.7	3.1	0.2	107%	-	-	-	-	-	-	6.4	104%	13.0	103%
Operating income	13.0	24.1	36.9	46.1	9.4	(3.6)	72%	-	-	-	-	-	-	12.0	50%	33.0	72%

(2) ProStrakan (GBP)

Millions of GBP, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	35.7	74.2	113.8	155.4	38.4	2.6	107%	-	-	-	-	-	-	81.4	110%	168.8	109%
Cancer pain																	
Abstral	10.5	22.1	34.3	47.1	12.1	1.6	115%	-	-	-	-	-	-	26.2	118%	55.4	118%
Chemotherapy-induced nausea and vomiting drug																	
Sancuso	3.0	6.2	9.3	13.8	2.7	(0.2)	90%	-	-	-	-	-	-	8.2	133%	17.9	130%
Replacement therapy with testosterone for male hypogonadism																	
Tostran	1.8	4.9	8.7	12.4	2.7	0.8	146%	-	-	-	-	-	-	6.4	131%	15.8	127%
Relief of pain associated with chronic anal fissures																	
Rectogesic	2.9	6.3	9.2	12.7	2.7	(0.2)	93%	-	-	-	-	-	-	6.1	97%	12.8	101%
Osteoporosis drug																	
Adcal-D3	6.7	13.5	20.6	28.4	7.1	0.3	106%	-	-	-	-	-	-	12.9	95%	28.1	99%
Others	7.0	14.0	20.8	26.6	7.9	0.8	113%	-	-	-	-	-	-	16.7	119%	33.3	125%
Product net sales (subtotal)	32.2	67.2	103.2	141.2	35.4	3.2	110%	-	-	-	-	-	-	76.6	114%	163.6	116%
Technology Out-Licensing and others	3.4	6.9	10.6	14.1	2.9	(0.5)	84%	-	-	-	-	-	-	4.7	69%	5.1	36%
Gross profit	27.4	57.0	87.6	116.5	28.8	1.3	105%	-	-	-	-	-	-	61.2	107%	123.5	106%
Selling, general and administrative expenses *1	19.3	39.7	56.8	75.0	17.8	(1.5)	92%	-	-	-	-	-	-	38.7	97%	75.9	101%
EBIDTA *2	8.0	17.2	30.8	41.5	10.9	2.8	136%	-	-	-	-	-	-	22.4	130%	47.6	115%
Goodwill amortization *1	9.9	19.9	29.8	39.9	9.9	(0.0)	100%	-	-	-	-	-	-	19.9	100%	40.6	102%
Operating income	(1.8)	(2.6)	0.9	1.5	1.0	2.8	-	-	-	-	-	-	-	2.5	-	6.9	450%

*1 Amortization of goodwill is not included in Selling, general and administrative expenses.

Goodwill amortization= Depreciation + Goodwill amortization

*2 EBITDA=Operating income + depreciation + goodwill amortization.

*3 Geographical breakdown of sales for Jan. - Mar. 2014 is as follows:

UK	Europe (excluding UK)	USA	Other
30.8%	47.5%	20.4%	1.3%

(3) Kyowa Medex Co., Ltd.

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	2.5	5.4	8.4	11.7	2.6	0.1	105%	-	-	-	-	-	-	5.9	109%	12.4	106%
Japan sales	2.0	4.5	6.9	9.6	2.1	0.0	105%	-	-	-	-	-	-	4.9	109%	10.3	108%
Biochemical Diagnostic Reagent	0.8	1.8	2.8	4.0	0.8	0.0	103%	-	-	-	-	-	-	1.9	105%	4.2	105%
Immunological Diagnostic Reagent	1.0	2.2	3.4	4.7	1.0	0.0	104%	-	-	-	-	-	-	2.4	109%	5.0	107%
Other	0.2	0.3	0.6	0.8	0.2	0.0	110%	-	-	-	-	-	-	0.5	134%	1.0	126%
Exports	0.4	0.9	1.5	2.1	0.5	0.0	109%	-	-	-	-	-	-	0.9	105%	2.1	99%
Operating income	0.0	0.2	0.4	0.8	0.0	0.0	108%	-	-	-	-	-	-	0.3	154%	1.1	129%

V. Segment information and main subsidiaries operating profit or loss

2. Bio-Chemicals segment

(1) Bio-Chemicals segment consolidated total

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	19.9	41.2	61.5	82.9	23.5	3.5	118%	-	-	-	-	-	-	45.5	110%	90.0	109%
Japan sales	11.5	23.4	35.3	48.0	12.9	1.3	112%	-	-	-	-	-	-	25.2	107%	49.8	104%
Overseas sales	8.4	17.7	26.2	34.8	10.6	2.2	127%	-	-	-	-	-	-	20.3	115%	40.2	115%
America	1.8	4.1	5.9	8.0	2.0	0.1	109%	-	-	-	-	-	-	4.9	118%	10.1	125%
Europe	3.6	7.5	11.0	14.1	4.1	0.5	115%	-	-	-	-	-	-	8.6	113%	16.2	114%
Asia and others	2.9	5.9	9.2	12.6	4.4	1.5	152%	-	-	-	-	-	-	6.8	114%	13.9	110%
Operating income	1.4	3.1	4.5	5.6	3.0	1.5	206%	-	-	-	-	-	-	4.0	129%	8.0	141%

(2) Kyowa Hakko Bio Co., Ltd

Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	13.8	27.8	42.2	57.5	17.3	3.4	125%	-	-	-	-	-	-	32.1	115%	62.9	109%
Japan sales	8.8	17.8	26.8	36.1	9.9	1.0	112%	-	-	-	-	-	-	19.4	109%	38.1	106%
Pharmaceutical and industrial materials	3.8	7.5	11.3	15.3	4.2	0.4	113%	-	-	-	-	-	-	7.4	99%	14.9	97%
Healthcare	2.4	5.3	8.0	11.0	2.6	0.2	108%	-	-	-	-	-	-	6.1	116%	12.5	114%
Other	2.5	5.0	7.3	9.7	2.9	0.3	115%	-	-	-	-	-	-	5.8	116%	10.7	110%
Exports	4.9	10.0	15.4	21.4	7.4	2.4	149%	-	-	-	-	-	-	12.6	127%	24.7	115%
Operating income	1.2	2.2	3.4	4.6	2.7	1.4	218%	-	-	-	-	-	-	2.9	133%	5.5	119%

(3) DAIICHI FINE CHEMICAL CO., LTD.









Billions of yen, rounded down

	FY 2013 results				FY 2014 results								FY 2014 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	2.9	5.8	8.4	12.1	3.5	0.6	121%	-	-	-	-	-	-	5.7	100%	12.7	105%
Operating income	(0.0)	(0.2)	(0.5)	(0.9)	(0.0)	(0.0)	-	-	-	-	-	-	-	(0.1)	-	0.5	-













VI. R&D Pipeline


Filed · Approved  antibody  protein  small molecule

As of Apr 17th, 2014

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in PH and CN	Licensed from NPS	
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients) Peripheral T-cell Lymphoma Cutaneous T-cell Lymphoma	Supplemental NDA in preparation in JP Approved in JP March 2014	In-House	POTELLIGENT® Supplemental NDA for ATL combination therapy temporarily withdrawn
		Granisetron Patch	5-HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in MY	Licensed from Solasia Pharma (ProStrakan)	Launched by ProStrakan as Sancuso®
		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Filed in JP	Kirin-Amgen	
		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Hypercalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Approved in JP February 2014	Licensed from NPS	
		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Myelodysplastic Syndrome related Anemia	Filed in JP	Kirin-Amgen	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Filed in US	In-House	
Other		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Filed in HK, SG, MY and TH	Kirin-Amgen	

Phase II, Phase III









Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Phase III in CN	Kirin-Amgen	
		Ⓞ RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Reata	The Phase II study conducted in JP has been discontinued, but a future development program for RTA 402 is under consideration.
		Ⓞ KHK7580 Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase I / II in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		Ⓞ ARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer Lung Cancer (EGF-receptor mutated) Gastric Cancer	Phase III in JP Phase II in JP Phase II in JP and KR	ArQule	
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Peripheral T-cell Lymphoma Adult T-cell Leukemia/Lymphoma Cutaneous T-cell Lymphoma	Phase II in EU Phase II in US, EU and others Phase III in US, EU and JP	In-House	POTELLIGENT®
		Ⓞ KW-2478 Injection	HSP90 Inhibitor	Multiple Myeloma	Phase I / II in UK, US and PH	In-House	
		Ⓞ KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase III in JP Phase II in KR	In-House	Jointly developed with AstraZeneca/MedImmune in Japan and South Korea POTELLIGENT®
		Ⓞ ASKP1240 Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in JP Phase II in US	In-House	Jointly developed with Astellas KM mouse
Immunology /Allergy		Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	Ulcerative Colitis Crohn's Disease	Phase III in JP Phase II in JP	Licensed from Zeria Pharma	Jointly developed with Zeria Pharma. The Phase III study is being conducted to test a new dose regimen
		Ⓞ KHK4827 Brodalumab Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase III in JP	Kirin-Amgen	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Phase III in US, EU and others	In-House	
	Other		Ⓞ KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase III in JP Phase I in EU	In-House



 Updated on Jan 24th, 2014 (Area, Stage, Filed, Approved, etc.)
Ⓞ New Molecular Entity

VI. R&D Pipeline

Ph I  antibody  protein  small molecule





As of Apr 17th, 2014

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		ⓄB I W-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase I / II a in KR	In-House	POTELLIGENT®
		ⓄKRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in JP	In-House	In development overseas by AVEO as AV-951
		ⓄCEP-37250/ KHK 2804 Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase I in US	Licensed from Teva	Jointly developed with Teva POTELLIGENT®
		ⓄKHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in SG	In-House	POTELLIGENT® KM mouse
Immunology /Allergy		KW-0761 Mogamulzumab Injection	Anti-CCR4 Humanized Antibody	Asthma	Phase I in JP	In-House	POTELLIGENT®
		ⓄKHK4083 Injection	Immunomodulator Antibody	Autoimmune diseases	Phase I in CA	In-House	POTELLIGENT® KM mouse
Other		ⓄKRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)	Phase I / II in US and CA	In-House	Jointly developed with Ultragenyx KM mouse
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase I in KR	Kirin-Amgen	





 Updated since Jan 24th, 2014 (Area, Stage, Filed, Approved etc.)
 New Molecular Entity

Updated since Jan 24th, 2014 (Area, Stage, Filed, Approved etc.)


Filed · Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Hypercalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Approved in JP February 2014	Licensed from NPS	
		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Myelodysplastic Syndrome related Anemia	Filed in Japan	Kirin-Amgen	
		KW-0761 Mogamulzumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients) Peripheral T-cell Lymphoma Cutaneous T-cell Lymphoma	Supplemental NDA in preparation in Japan Approved in JP March 2014	In-House	POTELLIGENT® Supplemental NDA for ATL combination therapy temporarily withdrawn
Other		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Filed in TH	Kirin-Amgen	

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		ⓄARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase III in JP	ArQule	
		KW-0761 Mogamulzumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma Cutaneous T-cell Lymphoma	Phase II in US, EU and others Phase III in US, EU and JP	In-House	POTELLIGENT®
Immunology /Allergy		ⓄKHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase III in JP	In-House	Jointly developed with AstraZeneca/MedImmune in JP and KR POTELLIGENT®
		ⓄKHK4577 Oral	Anti-inflammatory Agent	Atopic dermatitis	Phase II in JP	In-House	

Ph I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
others		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase I in KR	Kirin-Amgen	

<Appendix>Pipeline of Biosimilar (Fujifilm Kyowa Kirin Biologics)

Phase I

As of April 17th 2014

Code Name	Generic Name	Stage	Remarks
FKB327	Adalimumab (fully human anti-TNF- α monoclonal antibody)	Phase I in UK	